Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome

Stefan Faderl, Guillermo Garcia-Manero, Zeev Estrov, Farhad Ravandi, Gautam Borthakur, Jorge E. Cortes, Susan O'Brien, Varsha Gandhi, William Plunkett, Anna Byrd, Monica Kwari, Hagop M. Kantarjian

Research output: Contribution to journalArticle

Abstract

Purpose: Efficacy and toxicity profile of orally administered clofarabine were evaluated in patients with higher-risk myelodysplastic syndrome (MDS). Patients and Methods: Thirty-two patients were treated, of whom 22 had intermediate-2 or high-risk disease (International Prognostic Scoring System). Median age was 70 years (range, 53 to 86), nine patients had secondary MDS, and 20 patients experienced prior therapy failure with hypomethylating agents. Three doses of clofarabine were evaluated: 40 mg/m2, 30 mg/m2, and 20 mg/m2 daily for 5 days. Courses were repeated every 4 to 8 weeks. Results: Eight patients (25%) achieved complete remission (CR), three had (9%) hematologic improvement (HI), and three had (9%) clinical benefit (CB; overall response rate, 43%). Responses in patients who experience treatment failure with hypomethylating agents included CR in two (10%), HI in two (10%), and CB in two patients (10%). No patients died within 6 weeks of induction. Renal failure occurred in four patients in the context of myelosuppresssion- associated infectious complications. Common adverse events were gastrointestinal and hepatic. Myelosuppression was common, but prolonged myelosuppression (> 42 days) was rare. The toxicity profile was better with lower doses of clofarabine, whereas response rates did not differ significantly. Conclusion: Oral clofarabine has achieved a response rate of 43% in patients with higher-risk MDS. The optimal dose and schedule and the appropriate patient population for such therapy remain to be further defined.

Original languageEnglish (US)
Pages (from-to)2755-2760
Number of pages6
JournalJournal of Clinical Oncology
Volume28
Issue number16
DOIs
StatePublished - Jun 1 2010
Externally publishedYes

Fingerprint

Myelodysplastic Syndromes
Therapeutics
clofarabine
Treatment Failure
Renal Insufficiency
Appointments and Schedules

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Faderl, S., Garcia-Manero, G., Estrov, Z., Ravandi, F., Borthakur, G., Cortes, J. E., ... Kantarjian, H. M. (2010). Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. Journal of Clinical Oncology, 28(16), 2755-2760. https://doi.org/10.1200/JCO.2009.26.3509

Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. / Faderl, Stefan; Garcia-Manero, Guillermo; Estrov, Zeev; Ravandi, Farhad; Borthakur, Gautam; Cortes, Jorge E.; O'Brien, Susan; Gandhi, Varsha; Plunkett, William; Byrd, Anna; Kwari, Monica; Kantarjian, Hagop M.

In: Journal of Clinical Oncology, Vol. 28, No. 16, 01.06.2010, p. 2755-2760.

Research output: Contribution to journalArticle

Faderl, S, Garcia-Manero, G, Estrov, Z, Ravandi, F, Borthakur, G, Cortes, JE, O'Brien, S, Gandhi, V, Plunkett, W, Byrd, A, Kwari, M & Kantarjian, HM 2010, 'Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome', Journal of Clinical Oncology, vol. 28, no. 16, pp. 2755-2760. https://doi.org/10.1200/JCO.2009.26.3509
Faderl, Stefan ; Garcia-Manero, Guillermo ; Estrov, Zeev ; Ravandi, Farhad ; Borthakur, Gautam ; Cortes, Jorge E. ; O'Brien, Susan ; Gandhi, Varsha ; Plunkett, William ; Byrd, Anna ; Kwari, Monica ; Kantarjian, Hagop M. / Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. In: Journal of Clinical Oncology. 2010 ; Vol. 28, No. 16. pp. 2755-2760.
@article{98ca2369fe854fcf8cc8f29965aba3ad,
title = "Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome",
abstract = "Purpose: Efficacy and toxicity profile of orally administered clofarabine were evaluated in patients with higher-risk myelodysplastic syndrome (MDS). Patients and Methods: Thirty-two patients were treated, of whom 22 had intermediate-2 or high-risk disease (International Prognostic Scoring System). Median age was 70 years (range, 53 to 86), nine patients had secondary MDS, and 20 patients experienced prior therapy failure with hypomethylating agents. Three doses of clofarabine were evaluated: 40 mg/m2, 30 mg/m2, and 20 mg/m2 daily for 5 days. Courses were repeated every 4 to 8 weeks. Results: Eight patients (25{\%}) achieved complete remission (CR), three had (9{\%}) hematologic improvement (HI), and three had (9{\%}) clinical benefit (CB; overall response rate, 43{\%}). Responses in patients who experience treatment failure with hypomethylating agents included CR in two (10{\%}), HI in two (10{\%}), and CB in two patients (10{\%}). No patients died within 6 weeks of induction. Renal failure occurred in four patients in the context of myelosuppresssion- associated infectious complications. Common adverse events were gastrointestinal and hepatic. Myelosuppression was common, but prolonged myelosuppression (> 42 days) was rare. The toxicity profile was better with lower doses of clofarabine, whereas response rates did not differ significantly. Conclusion: Oral clofarabine has achieved a response rate of 43{\%} in patients with higher-risk MDS. The optimal dose and schedule and the appropriate patient population for such therapy remain to be further defined.",
author = "Stefan Faderl and Guillermo Garcia-Manero and Zeev Estrov and Farhad Ravandi and Gautam Borthakur and Cortes, {Jorge E.} and Susan O'Brien and Varsha Gandhi and William Plunkett and Anna Byrd and Monica Kwari and Kantarjian, {Hagop M.}",
year = "2010",
month = "6",
day = "1",
doi = "10.1200/JCO.2009.26.3509",
language = "English (US)",
volume = "28",
pages = "2755--2760",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "16",

}

TY - JOUR

T1 - Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome

AU - Faderl, Stefan

AU - Garcia-Manero, Guillermo

AU - Estrov, Zeev

AU - Ravandi, Farhad

AU - Borthakur, Gautam

AU - Cortes, Jorge E.

AU - O'Brien, Susan

AU - Gandhi, Varsha

AU - Plunkett, William

AU - Byrd, Anna

AU - Kwari, Monica

AU - Kantarjian, Hagop M.

PY - 2010/6/1

Y1 - 2010/6/1

N2 - Purpose: Efficacy and toxicity profile of orally administered clofarabine were evaluated in patients with higher-risk myelodysplastic syndrome (MDS). Patients and Methods: Thirty-two patients were treated, of whom 22 had intermediate-2 or high-risk disease (International Prognostic Scoring System). Median age was 70 years (range, 53 to 86), nine patients had secondary MDS, and 20 patients experienced prior therapy failure with hypomethylating agents. Three doses of clofarabine were evaluated: 40 mg/m2, 30 mg/m2, and 20 mg/m2 daily for 5 days. Courses were repeated every 4 to 8 weeks. Results: Eight patients (25%) achieved complete remission (CR), three had (9%) hematologic improvement (HI), and three had (9%) clinical benefit (CB; overall response rate, 43%). Responses in patients who experience treatment failure with hypomethylating agents included CR in two (10%), HI in two (10%), and CB in two patients (10%). No patients died within 6 weeks of induction. Renal failure occurred in four patients in the context of myelosuppresssion- associated infectious complications. Common adverse events were gastrointestinal and hepatic. Myelosuppression was common, but prolonged myelosuppression (> 42 days) was rare. The toxicity profile was better with lower doses of clofarabine, whereas response rates did not differ significantly. Conclusion: Oral clofarabine has achieved a response rate of 43% in patients with higher-risk MDS. The optimal dose and schedule and the appropriate patient population for such therapy remain to be further defined.

AB - Purpose: Efficacy and toxicity profile of orally administered clofarabine were evaluated in patients with higher-risk myelodysplastic syndrome (MDS). Patients and Methods: Thirty-two patients were treated, of whom 22 had intermediate-2 or high-risk disease (International Prognostic Scoring System). Median age was 70 years (range, 53 to 86), nine patients had secondary MDS, and 20 patients experienced prior therapy failure with hypomethylating agents. Three doses of clofarabine were evaluated: 40 mg/m2, 30 mg/m2, and 20 mg/m2 daily for 5 days. Courses were repeated every 4 to 8 weeks. Results: Eight patients (25%) achieved complete remission (CR), three had (9%) hematologic improvement (HI), and three had (9%) clinical benefit (CB; overall response rate, 43%). Responses in patients who experience treatment failure with hypomethylating agents included CR in two (10%), HI in two (10%), and CB in two patients (10%). No patients died within 6 weeks of induction. Renal failure occurred in four patients in the context of myelosuppresssion- associated infectious complications. Common adverse events were gastrointestinal and hepatic. Myelosuppression was common, but prolonged myelosuppression (> 42 days) was rare. The toxicity profile was better with lower doses of clofarabine, whereas response rates did not differ significantly. Conclusion: Oral clofarabine has achieved a response rate of 43% in patients with higher-risk MDS. The optimal dose and schedule and the appropriate patient population for such therapy remain to be further defined.

UR - http://www.scopus.com/inward/record.url?scp=77954911871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954911871&partnerID=8YFLogxK

U2 - 10.1200/JCO.2009.26.3509

DO - 10.1200/JCO.2009.26.3509

M3 - Article

C2 - 20421540

AN - SCOPUS:77954911871

VL - 28

SP - 2755

EP - 2760

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 16

ER -